- Oops!Something went wrong.Please try again later.
Shares of Edwards Lifesciences (NYSE:EW) decreased 2.5% in after-market trading after the company reported Q3 results.
Earnings per share decreased 63.83% year over year to $0.51, which beat the estimate of $0.44.
Revenue of $1,141,000,000 up by 4.30% year over year, which beat the estimate of $1,080,000,000.
Edwards Lifesciences Raises FY20 Adj. EPS Guidance From $1.75-$1.95 To $1.85-$1.95 vs $1.84 Est.
Details Of The Call
Date: Oct 21, 2020
Time: 05:00 PM
Company's 52-week high was at $247.64
Company's 52-week low was at $66.23
Price action over last quarter: Up 7.01%
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.